P. Fernández-Abellán

发表

Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96.

M. Tormo, A. Oriol, M. Sanz, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A prognostic model for survival after salvage treatment with FLAG‐Ida +/− gemtuzumab‐ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia

M. Sanz, M. Barrios, J. Serrano, 2016, British journal of haematology.

Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia.

Marcos González, J. Hernández-Rivas, A. Órfão, 2013, Leukemia research.

Practice of central nervous system prophylaxis and treatment in acute leukemias in Spain. Prospective registry study.

J. Sancho, J. Ribera, R. Arranz, 2008, Medicina clinica.

Results of Compassionate Therapy with Intrathecal Depot Liposomal Cytarabine in Acute Myeloid Leukemia Meningeosis

J. Sancho, L. Palomera, A. Parker, 2007, International journal of hematology.

Prognostic significance of complex karyotype and monosomal karyotype in adult patients with acute lymphoblastic leukemia treated with risk‐adapted protocols

M. Tormo, J. Hernández-Rivas, J. Cervera, 2014, Cancer.

Rituximab and autologous stem cell transplantation for malignant lymphoma after liver transplantation

B. Sánchez‐González, P. Fernández-Abellán, B. Villarrubia, 2004, Bone Marrow Transplantation.

Lack of influence of human immunodeficiency virus infection status in the response to therapy and survival of adult patients with mature B-cell lymphoma or leukemia. Results of the PETHEMA-LAL3/97 study.

J. Esteve, A. Oriol, M. Sanz, 2003, Haematologica.

Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial.

J. Esteve, L. Escoda, M. Tormo, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Autologous stem cell transplantation for primary refractory Hodgkin's disease: results and clinical variables affecting outcome.

J. Garcia-conde, M. Terol, F. Hernández-Navarro, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia.

Marcos González, J. S. San Miguel, J. Rodríguez, 2009, Blood.

Post-transplant Burkit t's Leukemia or Lymphoma. Study of Five Cases Treated with Specific Intensive Therapy (PETHEMA ALL-3/97 Trial)

J. Esteve, M. Sanz, S. Brunet, 2003, Leukemia & lymphoma.

Severe skin reaction to imatinib in a case of Philadelphia-positive acute lymphoblastic leukemia.

I. Belinchón-Romero, B. Sánchez‐González, J. C. Pascual-Ramírez, 2003, Blood.

Lack of negative impact of Philadelphia chromosome in older patients with acute lymphoblastic leukaemia in the thyrosine kinase inhibitor era: comparison of two prospective parallel protocols

M. Tormo, A. Oriol, S. Brunet, 2012, British journal of haematology.

High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogenetics.

Marcos González, J. S. San Miguel, J. Rodríguez, 2009, Leukemia research.